Adaptimmune Therapeutics plc – NASDAQ:ADAP

Add to watchlist

$0.061

-0.52

-89.64%

Market closed

Open in 5 minutes

-53.91%

month

-53.91%

quarter

-17.94%

year

Market Cap	148.71M
Enterprise value	1.10B

P/E	-1.2
EV/Sales	40.75
EV/EBITDA	-7.06
Price/Sales	43.88
Price/Book	14.55
PEG ratio	-0.01
EPS	-0.73

Revenue	18.36M
EBITDA	-211.52M
Income	-163.82M
Revenue Q/Q	-88.07%
Revenue Y/Y	-74.20%

Profit margin	-609.46%
Oper. margin	-503.62%
Gross margin	40.62%
EBIT margin	-503.62%
EBITDA margin	-1152.09%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Adaptimmune Therapeutics plc (NASDAQ:ADAP): Profit margin
Jun 2023	5.13M	-21.38M	-416.94%
Sep 2023	7.31M	-45.60M	-623.05%
Dec 2023	233.00K	-48.33M	-20743.33%
Mar 2024	5.67M	-48.50M	-854.23%

Adaptimmune Therapeutics Financials Estimate

Q Y

Adaptimmune Therapeutics plc (NASDAQ:ADAP): Analyst Estimates
Sep 2025	6.95M	-23.59M	-339.43%
Dec 2025	8.05M	-31.07M	-386.01%
Mar 2026	20.24M	-37.53M	-185.4%
Jun 2026	23.73M	-36.20M	-152.55%

Analysts Price target
Financials & Ratios estimates

Adaptimmune Therapeutics plc (NASDAQ:ADAP): Earnings per share (EPS)
2023-03-06	-0.13046	-0.18

Adaptimmune Therapeutics plc (NASDAQ:ADAP): Debt to assets
Jun 2023	342984000	216.33M	63.07%
Sep 2023	296638000	208.50M	70.29%
Dec 2023	282616000	243.10M	86.02%
Mar 2024	258010000	233.63M	90.55%

Adaptimmune Therapeutics plc (NASDAQ:ADAP): Cash Flow
Jun 2023	-43.76M	2.69M	14K
Sep 2023	-45.15M	57.30M	596K
Dec 2023	-14.66M	68.40M	73.85K
Mar 2024	-31.93M	-357.79K	29.21M

Adaptimmune Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Adaptimmune Therapeutics
Employees

Adaptimmune Therapeutics plc (NASDAQ:ADAP): Employee count
Aug 2023	534
Sep 2023	534
Oct 2023	534
Nov 2023	534
Dec 2023	534
Jan 2024	534
Feb 2024	534
Mar 2024	449
Apr 2024	449
May 2024	449
Jun 2024	449
Jul 2024	449

Adaptimmune Therapeutics
Hedge Funds Holdings Q1 2022

11.77% -0.42%

of ADAP is owned by hedge funds

76 -6

hedge funds hold ADAP stock

110.05M -3.42M

shares is hold by hedge funds

ADAP hedge funds holdings changes

Adaptimmune Therapeutics
Insider Trading

Adaptimmune Therapeutics plc (NASDAQ:ADAP): Insider trades (number of shares)
Period	Buy	Sel
Jul 2023	0	47702
Aug 2023	0	3096
Sep 2023	0	2403
Jan 2024	0	165799
Jun 2024	0	24531

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 Jun 2024	PICCINA CINTIA officer: Chief Commercial Officer officer: Chief Commercial Officer	American Depositary Shares representing Ordinary Shares	24,531	$0.93	$22,814
Sale	17 Jan 2024	RAWCLIFFE ADRIAN director, officer..	American Depositary Shares representing Ordinary Shares	30,080	$0.67	$20,244
Sale	17 Jan 2024	NORRY ELLIOT officer: Chief Medical Officer officer: Chief Medical Officer	American Depositary Shares representing Ordinary Shares	12,967	$0.67	$8,727
Sale	17 Jan 2024	NORRY ELLIOT officer: Chief Medical Officer officer: Chief Medical Officer	American Depositary Shares representing Ordinary Shares	5,309	$0.67	$3,573
Sale	17 Jan 2024	LUNGER JOHN officer: Chief Pa..	American Depositary Shares representing Ordinary Shares	12,805	$0.67	$8,618
Sale	17 Jan 2024	LUNGER JOHN officer: Chief Pa..	American Depositary Shares representing Ordinary Shares	5,309	$0.67	$3,573
Sale	17 Jan 2024	BERTRAND WILLIAM C JR officer: Chief Op..	American Depositary Shares representing Ordinary Shares	13,599	$0.67	$9,152
Sale	17 Jan 2024	BERTRAND WILLIAM C JR officer: Chief Op..	American Depositary Shares representing Ordinary Shares	5,309	$0.67	$3,573
Sale	16 Jan 2024	RAWCLIFFE ADRIAN director, officer..	American Depositary Shares representing Ordinary Shares	9,304	$0.79	$7,350
Sale	16 Jan 2024	NORRY ELLIOT officer: Chief Medical Officer officer: Chief Medical Officer	American Depositary Shares representing Ordinary Shares	2,287	$0.79	$1,807

ADAP insider trading transactions

Adaptimmune Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 15 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 6 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 8 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 9 Aug 2023	Q2 2023 Earnings Call Transcript

ADAP earnings call transcripts

Adaptimmune Therapeutics
Executives

Insider	Age	Compensation
Mr. Adrian G. Rawcliffe (1972) Chief Executive Officer, Principal Accounting Officer & Director	53	$986,260
Dr. Helen Katrina Tayton-Martin MBA, Ph.D. (1967) Co-Founder & Chief Bus. Officer	58	$703,670
Mr. William C. Bertrand Jr. (1965) Chief Operating Officer	60	$693,450
Mr. John Lunger (1970) Chief Patient Supply Officer	55	$629,800
Mr. Gavin Hilary James Wood BA (Hons), ACA (1970) Chief Financial Officer	55	$577,640

Adaptimmune Therapeutics
Latest News

Thursday, 19 December 2024
07:30	Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK	newsfilecorp.com
Monday, 2 December 2024
16:00	First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)	newsfilecorp.com
Wednesday, 13 November 2024
19:48	Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript	seekingalpha.com
16:05	Adaptimmune Reports Q3 2024 Financial and Business Updates	newsfilecorp.com
09:00	Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial	newsfilecorp.com
Tuesday, 5 November 2024
09:19	Adaptimmune to Participate in Scientific and Medical Conferences this November and December	newsfilecorp.com
Thursday, 31 October 2024
17:20	Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024	newsfilecorp.com
Wednesday, 28 August 2024
08:00	Adaptimmune to Participate in Two Bank Conferences this September	newsfilecorp.com
Monday, 12 August 2024
11:42	Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript	seekingalpha.com
07:00	Adaptimmune Reports Q2 2024 Financial and Business Updates	newsfilecorp.com
Monday, 5 August 2024
08:00	Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024	newsfilecorp.com
Friday, 2 August 2024
09:20	US FDA approves Adaptimmune's gene therapy for rare type of cancer	reuters.com
Thursday, 1 August 2024
22:56	STM Investors Have Opportunity to Join STMicroelectronics N.V. Fraud Investigation with the Schall Law Firm	businesswire.com
20:20	Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor	businesswire.com
Wednesday, 3 July 2024
09:54	Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024	seekingalpha.com
Monday, 17 June 2024
14:05	ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company	benzinga.com
Monday, 3 June 2024
12:00	Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise	newsfilecorp.com
Thursday, 30 May 2024
16:01	Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications	newsfilecorp.com
16:01	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications	globenewswire.com
Wednesday, 15 May 2024
10:07	Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript	seekingalpha.com
07:30	Adaptimmune Reports Q1 2024 Financial and Business Updates	newsfilecorp.com
07:00	Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital	newsfilecorp.com
Wednesday, 1 May 2024
12:00	Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024	Newsfile Corp
Monday, 15 April 2024
15:16	Adaptimmune (ADAP) Down on End of Collaboration With Roche	Zacks Investment Research
Tuesday, 16 January 2024
12:47	Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why	Zacks Investment Research
Thursday, 30 November 2023
12:01	Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND	Zacks Investment Research
Monday, 13 November 2023
11:19	Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner	Zacks Investment Research
Tuesday, 7 November 2023
19:32	Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing	Zacks Investment Research
Friday, 27 October 2023
19:33	Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights	Zacks Investment Research
Wednesday, 25 October 2023
08:06	Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023	Newsfile Corp

Ideas & Opinions

Seeking Alpha 3 Jul 2024

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Seeking Alpha 26 Apr 2024

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Seeking Alpha 25 Apr 2024

These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Seeking Alpha 12 Sep 2023

Adaptimmune: Spinning Sarcoma Into Gold
Seeking Alpha 21 Apr 2023

Adaptimmune Shareholders Can Lock In A Big Merger Spread By Swapping To TCR2 Therapeutics
Seeking Alpha 26 Mar 2023

Adaptimmune: TCR2 Merger Represents Opportunity For Enthusiastic Investors
Seeking Alpha 9 Dec 2022

Adaptimmune: The Afamicel Rolling BLA Is Its Lifeline
Seeking Alpha 27 Oct 2022

Alpine: Ramifications Of The Davoceticept Termination
Seeking Alpha 29 Jun 2022

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Seeking Alpha 19 Jun 2022

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Frequently Asked Questions (FAQ)

What's the price of Adaptimmune Therapeutics stock today?

One share of Adaptimmune Therapeutics stock can currently be purchased for approximately $0.06.
When is Adaptimmune Therapeutics's next earnings date?

Unfortunately, Adaptimmune Therapeutics's (ADAP) next earnings date is currently unknown.
Does Adaptimmune Therapeutics pay dividends?

No, Adaptimmune Therapeutics does not pay dividends.
How much money does Adaptimmune Therapeutics make?

Adaptimmune Therapeutics has a market capitalization of 148.71M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 122.05% to 60.28M US dollars. Adaptimmune Therapeutics made a loss 113.87M US dollars in net income (profit) last year or -$0.18 on an earnings per share basis.
What is Adaptimmune Therapeutics's stock symbol?

Adaptimmune Therapeutics plc is traded on the NASDAQ under the ticker symbol "ADAP".
What is Adaptimmune Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Adaptimmune Therapeutics?

Shares of Adaptimmune Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Adaptimmune Therapeutics's key executives?
Adaptimmune Therapeutics's management team includes the following people:
- Mr. Adrian G. Rawcliffe Chief Executive Officer, Principal Accounting Officer & Director(age: 53, pay: $986,260)
- Dr. Helen Katrina Tayton-Martin MBA, Ph.D. Co-Founder & Chief Bus. Officer(age: 58, pay: $703,670)
- Mr. William C. Bertrand Jr. Chief Operating Officer(age: 60, pay: $693,450)
- Mr. John Lunger Chief Patient Supply Officer(age: 55, pay: $629,800)
- Mr. Gavin Hilary James Wood BA (Hons), ACA Chief Financial Officer(age: 55, pay: $577,640)
Is Adaptimmune Therapeutics founder-led company?

Yes, Adaptimmune Therapeutics is a company led by its founder Dr. Helen Katrina Tayton-Martin MBA, Ph.D..
How many employees does Adaptimmune Therapeutics have?

As Jul 2024, Adaptimmune Therapeutics employs 449 workers.
When Adaptimmune Therapeutics went public?

Adaptimmune Therapeutics plc is publicly traded company for more then 10 years since IPO on 6 May 2015.
What is Adaptimmune Therapeutics's official website?

The official website for Adaptimmune Therapeutics is adaptimmune.com.
How can i contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics can be reached via phone at +44 1235 430000.

Adaptimmune Therapeutics plc

adaptimmune.com

Exchange:

NASDAQ

Full time employees:

449

Industry:

Biotechnology

Sector:

Healthcare

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

+44 1235 430000

60 Jubilee Avenue
Abingdon, OX14 4RX

CIK: 0001621227
ISIN: US00653A1079
CUSIP: 00653A107